Observational studyBMC endocrine disorders2026
Triglyceride-glucose index as a potential evaluation tool for all-cause mortality in ischemic stroke patients undergoing endovascular therapy: a multicenter cohort study.
Observational study in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe triglyceride-glucose (TyG) index has demonstrated a significant association with stroke outcomes. However, its prognostic value in acute ischemic stroke (AIS) patients undergoing endovascular therapy (EVT) remains inadequately explored. This study aims to evaluate the association between the TyG index and all-cause mortality in AIS patients undergoing EVT.
methodsThis was a multicenter, retrospective cohort study that included AIS patients undergoing EVT between September 2018 and January 2024. Kaplan-Meier survival analysis was performed to evaluate survival differences across TyG tertiles for both in-hospital and 90-day. Cox proportional hazards regression and restricted cubic splines (RCS) were used to examine the association between the TyG index and all-cause mortality. Additionally, interaction and subgroup analyses were conducted to evaluate the robustness and consistency of the results.
resultsAmong EVT patients (median age 69 years, 56.0% male), the in-hospital and 90-day mortality rates were 7.9% and 19.1%, respectively. Cox regression analysis revealed that an elevated TyG index was significantly associated with both in-hospital mortality (adjusted hazard ratio [HR] = 1.79; 95% CI = 1.27–2.53; P < 0.001) and 90-day mortality (HR = 1.44; 95% CI = 1.16–1.79; P < 0.001). RCS analysis demonstrated a positive linear relationship between the TyG index and all-cause mortality. Importantly, subgroup analysis revealed that diabetes modified the relationship between the TyG index and mortality, with a stronger effect in the non-diabetic subgroup (P for interaction = 0.011 and 0.022, respectively).
conclusionThe TyG index is significantly associated with all-cause mortality in non-diabetic AIS patients undergoing EVT, suggesting that it may serve as a potential evaluation tool for risk stratification in this patient population. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.